Skip to main content
S&P 5007,623.68-0.52%DOW52,215.16-1.23%NASDAQ25,955.34-0.21%BTC$80,327.00+0.07%ETH$2,327.63+0.07%GOLD$4,030.90+0.57%OIL$101.29-1.92%
Smart Investors Daily
SID Premium
CA

NASDAQ · CARL

CARLSMED, INC.

Healthcare · Medical - Healthcare Information Services

$14.53

Down-$0.08 (-0.55%)

Updated Oct 26, 2026, 10:02 AM

SID Score

4.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
348.63M
P/E ratio
-10.74
Dividend yield
0.00%
52-week range
$8.50 – $17.23
Volume
55.64K
Avg. volume
96.69K

Price performance · CARL

CARL price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 23, 2026

CARL closed at $14.53 after 20 trading sessions, up 2.47% for the selected period.

Last close
$14.53
Period change
+2.47%
Period low
$13.41
Period high
$15.30
Daily close
View OHLC price history
CARL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 23, 2026$14.61$14.785$14.35$14.5355.64K
Oct 22, 2026$14.35$14.805$14.16$14.6154.58K
Oct 21, 2026$14.17$14.9912$14.16$14.31129.33K
Oct 20, 2026$13.69$14.425$13.53$14.1850.71K
Oct 19, 2026$13.50$14.14$13.31$13.6655.68K
Oct 16, 2026$13.96$14.30$13.41$13.4173.23K
Oct 15, 2026$13.91$14.32$13.85$13.9533.28K
Oct 14, 2026$14.38$14.58$13.76$13.8552.08K
Oct 13, 2026$14.87$15.00$14.43$14.4748.43K
Oct 12, 2026$14.63$14.945$14.595$14.7836.91K
Oct 9, 2026$14.02$14.585$14.00$14.4264.5K
Oct 8, 2026$14.36$14.36$13.75$14.0562.78K
Oct 7, 2026$14.55$14.84$14.36$14.3852.09K
Oct 6, 2026$15.43$15.43$14.555$14.64116.19K
Oct 5, 2026$14.39$15.40$14.27$15.30130.64K
Oct 2, 2026$13.97$14.6115$13.696$14.27151.65K
Oct 1, 2026$14.12$14.54$13.45$13.76158.84K
Sep 30, 2026$13.99$14.13$13.56$14.0756.8K
Sep 29, 2026$14.14$14.2064$13.63$14.0953.83K
Sep 28, 2026$14.88$14.88$14.10$14.1852.94K

Latest CARL news

The latest Smart Investors Daily articles mentioning CARL.

Stock researchCompany · Overview

CARL research

Overview

Company profile and research snapshot.

Company profile

Carlsmed Inc is a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. It is focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of AI-enabled software solutions, and interbody implants that it custom design for each patient's unique pathology and vertebral bone topography, and single-use surgical instruments. The Company designs, manufactures, and markets aprevo, a comprehensive technology platform for spine fusion surgery procedures.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.00
Implied upside
—
Analysts
—
CARL recent ratings
DateFirmRatingTarget
Oct 12, 2026BTIGBuy—
Sep 28, 2026BTIGBuy—
Aug 6, 2026Truist SecuritiesBuy—
Jul 1, 2026NeedhamBuy—
May 6, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 14, 2026

Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System

CARLSBAD, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior System at the North American Spine Society’s 41st Annual Meeting (NASS) in San Antonio, TX. The launch follows a limited market evaluation that commenced in February 2026, with the first in human procedure completed on February 10, 2026. “The launch of the Bi-lateral System further expands our propri

Yahoo · Oct 2, 2026

Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that on September 28, 2026, it granted stock options to purchase 180,137 shares of the Company’s common stock and 89,286 time-based restricted stock units (“RSUs”) to Richard Heppenstall, the Company’s newly-hired Chief Financial Officer, as a material inducement to his employment.

Yahoo · Oct 1, 2026

Carlsmed Appoints Tony Jarc as Chief Product and AI Officer

CARLSBAD, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Tony Jarc, Ph.D. has been appointed to the newly-created position of Chief Product and AI Officer, effective immediately. Dr. Jarc will lead the development and commercialization of the Company’s next generation technology platform, surgical UI/UX, and personalized spine surge

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By